基于生物信息学探索支气管哮喘中的潜在差异免疫基因和免疫浸润特征

doi:10.6040/j.issn.1671-7554.0.2024.0079

摘要/Abstract

摘要： 目的识别支气管哮喘发生发展过程中差异表达的免疫关键基因和免疫细胞,并探讨两者之间的相关性。方法从公共基因表达数据库(gene expression omnibus, GEO)和Import数据库中分别下载哮喘相关数据集和免疫相关基因,利用R软件分析获得GSE76262中差异表达的免疫相关基因(differentially expressed immune-related genes, DE-IRGs)。在STRING数据库中明确DE-IRGs间的相互作用。使用Cytoscape软件中的CytoHubba插件筛选关键的DE-IRGs,并在GSE137268中进行验证。利用受试者工作特征(receiver operating characteristic, ROC)曲线评估关键DE-IRGs作为生物标志物的潜力。此外,单样本基因集富集分析(single-sample gene set enrichment analysis, ssGSEA)算法被用来分析28种免疫细胞在哮喘和健康者中的表达差别,使用斯皮尔曼相关系数评估关键免疫基因与免疫细胞之间的相关性。结果在GSE76262中鉴定出17个DE-IRGs,经PPI网络的筛选和在GSE137268中的验证,CCL22、CCR7、IL1R2、IL18R1、TNFAIP3和VEGFA被识别为哮喘患者诱导痰中的关键DE-IRGs且具有较高的诊断价值。此外,ssGSEA的结果提示哮喘患者存在明显的免疫失衡,与健康者相比,11种免疫细胞在哮喘患者诱导痰中的浸润明显增加。同时,CCL22、CCR7、IL1R2、IL18R1、VEGFA、TNFAIP3与浸润的免疫细胞呈显著正相关。结论 CCL22、CCR7、IL1R2、IL18R1、VEGFA、TNFAIP3可作为哮喘的潜在生物标志物,且可能参与调控其发病过程中免疫细胞的浸润。

关键词: 支气管哮喘, 免疫基因, 生物标志物, 免疫浸润

Abstract: Objective To identify immunologically critical genes and immune cells that are differentially expressed during the development of asthma and to explore the correlation between them. Methods The asthma-related datasets and immune-related genes were downloaded from the Gene Expression Omnibus database(GEO)and Import database, respectively, and analyzed using R software to obtain differentially expressed immune-related genes(DE-IRGs)in GSE76262. The interactions between DE-IRGs were clarified in the STRING database. Key DE-IRGs were screened using the CytoHubba plugin in Cytoscape software and validated in GSE137268. Receiver operating characteristic(ROC)curves were used to assess the potential of critical DE-IRGs as biomarkers. The single-sample gene set enrichment analysis(ssGSEA)algorithm was used to examine the differential expression of 28 immune cells in asthmatic and healthy individuals. Spearman correlation coefficients were used to evaluate the correlation between key immune genes and immune cells. Results Seventeen DE-IRGs were identified in GSE76262, and CCL22, CCR7, IL1R2, IL18R1, TNFAIP3, and VEGFA were identified as critical DE-IRGs in induced sputum from asthmatics with high diagnostic value, as screened by the PPI network and validated in GSE137268. In addition, the results of ssGSEA suggested a significant immune imbalance in asthmatics, with 11 types of immune cells significantly infiltrated in the induced sputum of asthmatics compared to healthy individuals. Meanwhile, CCL22, CCR7, IL1R2, IL18R1, VEGFA, and TNFAIP3 were positively correlated with infiltrated immune cells. Conclusion CCL22, CCR7, IL1R2, IL18R1, VEGFA, and TNFAIP3 serve as potential biomarkers of asthma and may modulate infiltration of immune cells in its pathogenesis.

Key words: Bronchial asthma, Immune-related genes, Biomarkers, Immune infiltration

中图分类号:

R562.2

石硕川,曾荣,张锦涛,张东,潘云,刘晓菲,许长娟,王莹,董亮. 基于生物信息学探索支气管哮喘中的潜在差异免疫基因和免疫浸润特征[J]. 山东大学学报 (医学版), 2024, 62(5): 43-53.

SHI Shuochuan, ZENG Rong, ZHANG Jintao, ZHANG Dong, PAN Yun, LIU Xiaofei, XU Changjuan, WANG Ying, DONG Liang. Bioinformatics-based exploration of potential differential immune genes and immune infiltration signatures in bronchial asthma[J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 43-53.

参考文献

[1] 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048. Asthma Group of Chinese Throacic Society. Guidelines for bronchial asthma prevent and management(2020 edition)Asthma Group of Chinese Throacic Society[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2020, 43(12): 1023-1048.
[2] Huang KW, Yang T, Xu JY, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196): 407-418.
[3] Kyvsgaard JN, Brustad N, Hesselberg LM, et al. Key risk factors of asthma-like symptoms are mediated through infection burden in early childhood[J]. J Allergy Clin Immunol, 2024, 153(3): 684-694.
[4] Kyvsgaard JN, Chawes BL, Horner DLG, et al. Risk factors and age-related patterns of asthma-like symptoms in early childhood[J]. J Allergy Clin Immunol Pract, 2023, 11(6): 1773-1784.e10.
[5] Potaczek DP, Miethe S, Schindler V, et al. Role of airway epithelial cells in the development of different asthma phenotypes[J]. Cell Signal, 2020, 69: 109523. doi:10.1016/j.cellsig.2019.109523.
[6] Hammad H, Lambrecht BN. The basic immunology of asthma[J]. Cell, 2021, 184(9): 2521-2522.
[7] Murphy RC, Lai Y, Liu M, et al. Distinct epithelial-innate immune cell transcriptional circuits underlie airway hyperresponsiveness in asthma[J]. Am J Respir Crit Care Med, 2023, 207(12): 1565-1575.
[8] Guida G, Riccio AM. Immune induction of airway remodeling[J]. Semin Immunol, 2019, 46: 101346. doi:10.1016/j.smim.2019.101346.
[9] Benson M. Clinical implications of omics and systems medicine: focus on predictive and individualized treatment[J]. J Intern Med, 2016, 279(3): 229-240.
[10] Ray A, Camiolo M, Fitzpatrick A, et al. Are we meeting the promise of endotypes and precision medicine in asthma?[J]. Physiol Rev, 2020, 100(3): 983-1017.
[11] Papi A, Brightling C, Pedersen SE, et al. Asthma[J]. Lancet, 2018, 391(10122): 783-800.
[12] Charles D, Shanley J, Temple SN, et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis[J]. Clin Exp Allergy, 2022, 52(5): 616-627.
[13] Brusselle GG, Koppelman GH. Biologic therapies for severe asthma[J]. N Engl J Med, 2022, 386(2): 157-171.
[14] Maglio A, Vitale C, Pellegrino S, et al. Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma[J]. Biomedicines, 2021, 9(11): 1550. doi:10.3390/biomedicines9111550.
[15] Feng B, Zhou T, Guo ZY, et al. Comprehensive analysis of immune-related genes for classification and immune microenvironment of asthma[J]. Am J Transl Res, 2023, 15(2): 1052-1062.
[16] Daley D, Park JE, He JQ, et al. Associations and interactions of genetic polymorphisms in innate immunity genes with early viral infections and susceptibility to asthma and asthma-related phenotypes[J]. J Allergy Clin Immunol, 2012, 130(6): 1284-1293.
[17] Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor(VEGF)induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung[J]. Nat Med, 2004, 10(10): 1095-1103.
[18] Pilette C, Francis JN, Till SJ, et al. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge[J]. Eur Respir J, 2004, 23(6): 876-884.
[19] Lo CY, Michaeloudes C, Bhavsar PK, et al. Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma[J]. J Allergy Clin Immunol, 2015, 135(5): 1186-1195.e1-6.
[20] Camiolo MJ, Zhou XX, Wei Q, et al. Machine learning implicates the IL-18 signaling axis in severe asthma[J]. JCI Insight, 2021, 6(21): e149945. doi:10.1172/jci.insight.149945.
[21] Liu Y, Xu K, Yao Y, et al. Current research into A20 mediation of allergic respiratory diseases and its potential usefulness as a therapeutic target[J]. Front Immunol, 2023, 14: 1166928. doi:10.3389/fimmu.2023.1166928.
[22] Poto R, Criscuolo G, Marone G, et al. Human lung mast cells: therapeutic implications in asthma[J]. Int J Mol Sci, 2022, 23(22): 14466. doi:10.3390/ijms232214466.
[23] Siddiqui S, Bachert C, Bjermer L, et al. Eosinophils and tissue remodeling: relevance to airway disease[J]. J Allergy Clin Immunol, 2023, 152(4): 841-857.
[24] Felton JM, Dorward DA, Cartwright JA, et al. Mcl-1 protects eosinophils from apoptosis and exacerbates allergic airway inflammation[J]. Thorax, 2020, 75(7): 600-605.
[25] van der Veen TA, de Groot LES, Melgert BN. The different faces of the macrophage in asthma[J]. Curr Opin Pulm Med, 2020, 26(1): 62-68.
[26] Abdelaziz MH, Abdelwahab SF, Wan J, et al. Alternatively activated macrophages; a double-edged sword in allergic asthma[J]. J Transl Med, 2020, 18(1): 58. doi:10.1186/s12967-020-02251-w.
[27] Mamessier E, Nieves A, Lorec AM, et al. T-cell activation during exacerbations: a longitudinal study in refractory asthma[J]. Allergy, 2008, 63(9): 1202-1210.
[28] Smyth LJ, Eustace A, Kolsum U, et al. Increased airway T regulatory cells in asthmatic subjects[J]. Chest, 2010, 138(4): 905-912.
[29] Boonpiyathad T, Capova G, Duchna HW, et al. Impact of high-altitude therapy on type-2 immune responses in asthma patients[J]. Allergy, 2020, 75(1): 84-94.
[30] Boonpiyathad T, Sokolowska M, Morita H, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy[J]. Allergy, 2019, 74(5): 976-985.
[31] Xie Y, Abel PW, Casale TB, et al. TH17 cells and corticosteroid insensitivity in severe asthma[J]. J Allergy Clin Immunol, 2022, 149(2): 467-479.
[32] Vollmer CM, Dias ASO, Lopes LM, et al. Leptin favors Th17/Treg cell subsets imbalance associated with allergic asthma severity[J]. Clin Transl Allergy, 2022, 12(6): e12153. doi:10.1002/clt2.12153.
[33] Lin K, Wang T, Tang QQ, et al. IL18R1-related molecules as biomarkers for asthma severity and prognostic markers for idiopathic pulmonary fibrosis[J]. J Proteome Res, 2023, 22(10): 3320-3331.
[34] Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine[J]. Int Immunol, 1999, 11(1): 81-88.
[35] Nakano K, Whitehead GS, Lyons-Cohen MR, et al. Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation[J]. J Allergy Clin Immunol, 2024, 153(2): 487-502.e9.
[36] Fainaru O, Shseyov D, Hantisteanu S, et al. Accelerated chemokine receptor 7-mediated dendritic cell migration in Runx3 knockout mice and the spontaneous development of asthma-like disease[J]. Proc Natl Acad Sci U S A, 2005, 102(30): 10598-10603.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed